Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Treasury Shares (2023 - 2025)

Historic Treasury Shares for 4D Molecular Therapeutics (FDMT) over the last 3 years, with Q3 2025 value amounting to $698019.0.

  • 4D Molecular Therapeutics' Treasury Shares rose 11237.88% to $698019.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $698019.0, marking a year-over-year increase of 11237.88%. This contributed to the annual value of $361997.0 for FY2024, which is 9979.85% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Treasury Shares of $698019.0 as of Q3 2025, which was up 11237.88% from $725101.0 recorded in Q2 2025.
  • 4D Molecular Therapeutics' Treasury Shares' 5-year high stood at $748380.0 during Q1 2025, with a 5-year trough of $181181.0 in Q4 2023.
  • Over the past 3 years, 4D Molecular Therapeutics' median Treasury Shares value was $345332.0 (recorded in 2024), while the average stood at $438920.2.
  • In the last 5 years, 4D Molecular Therapeutics' Treasury Shares soared by 9979.85% in 2024 and then soared by 25654.12% in 2025.
  • Over the past 3 years, 4D Molecular Therapeutics' Treasury Shares (Quarter) stood at $181181.0 in 2023, then skyrocketed by 99.8% to $361997.0 in 2024, then soared by 92.82% to $698019.0 in 2025.
  • Its Treasury Shares stands at $698019.0 for Q3 2025, versus $725101.0 for Q2 2025 and $748380.0 for Q1 2025.